Fisher Asset Management LLC Makes New $757,000 Investment in Tyra Biosciences, Inc. $TYRA

Fisher Asset Management LLC purchased a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 28,800 shares of the company’s stock, valued at approximately $757,000. Fisher Asset Management LLC owned about 0.05% of Tyra Biosciences as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Chung Wu Investment Group LLC purchased a new position in Tyra Biosciences in the 4th quarter worth approximately $53,000. Federated Hermes Inc. increased its stake in Tyra Biosciences by 586.3% in the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after purchasing an additional 1,841 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Tyra Biosciences by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after purchasing an additional 534 shares during the period. SG Americas Securities LLC purchased a new position in Tyra Biosciences in the 3rd quarter worth approximately $133,000. Finally, Russell Investments Group Ltd. increased its stake in Tyra Biosciences by 27.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock worth $178,000 after purchasing an additional 2,766 shares during the period. 84.14% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on TYRA shares. Cantor Fitzgerald started coverage on Tyra Biosciences in a research note on Tuesday, February 24th. They issued an “overweight” rating on the stock. Wedbush raised their price target on shares of Tyra Biosciences from $37.00 to $53.00 and gave the stock an “outperform” rating in a report on Friday, February 13th. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of Tyra Biosciences in a report on Thursday, May 14th. Piper Sandler raised their price target on shares of Tyra Biosciences from $42.00 to $56.00 and gave the stock an “overweight” rating in a report on Friday, March 20th. Finally, William Blair started coverage on shares of Tyra Biosciences in a report on Tuesday, February 10th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Tyra Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $46.50.

Tyra Biosciences Stock Performance

NASDAQ TYRA opened at $33.41 on Friday. Tyra Biosciences, Inc. has a fifty-two week low of $8.88 and a fifty-two week high of $40.65. The stock has a market cap of $1.99 billion, a P/E ratio of -15.33 and a beta of 0.79. The stock has a 50 day simple moving average of $35.65 and a two-hundred day simple moving average of $30.27.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Sell-side analysts predict that Tyra Biosciences, Inc. will post -2.69 earnings per share for the current year.

Insider Buying and Selling

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of the company’s stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the completion of the transaction, the director directly owned 28,231 shares in the company, valued at approximately $1,043,700.07. This represents a 33.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 12.50% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.